GBS

Vital Energy Announces Early Results and Increase of its Cash Tender Offers for its Senior Notes due 2028 and Senior Notes due 2030; Planned Redemption of Senior Notes due 2028

Retrieved on: 
Thursday, March 28, 2024
Trustee, Tender offer, BofA Securities, Note, GBS, Tender, Security (finance)

The Withdrawal Deadline for the Tender Offers was 5:00 p.m., New York City time, on March 27, 2024.

Key Points: 
  • The Withdrawal Deadline for the Tender Offers was 5:00 p.m., New York City time, on March 27, 2024.
  • As a result, Tender Notes tendered pursuant to the Tender Offers may no longer be withdrawn, unless the Withdrawal Deadline is extended by the Company or as required by law.
  • The Tender Offers are not conditioned on any minimum principal amount of Tender Notes being tendered.
  • The Company has retained GBS to act as the information and tender agent in respect of the Tender Offers.

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Research, Brain, Geographic atrophy, Disease, RWE, International, Paratriathlon, Patient, ARCHER, G&A, Pivotal, EMA, Meta-analysis, Eye, European Medicines Agency, Medicine, Visual acuity, Immunoglobulin therapy, GBS, Facial muscles, Clinical trial, POC, Safety, Pharmacokinetics, Investment, SAD, FDA, BLA, AFL, CAD, Food, Pharmaceutical industry

BRISBANE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.

Key Points: 
  • Finally, we anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year.
  • ANX005 in GBS: First-in-class monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain.
  • ANX005 in GBS: Topline data from pivotal, randomized, placebo-controlled Phase 3 trial expected in the second quarter of 2024.
  • Cash and operating runway: Cash and cash equivalents and short-term investments were $259.7 million as of December 31, 2023.

Gate.io Participated In The 2024 Hong Kong Web3 Festival Along With Other Industry Leaders

Retrieved on: 
Saturday, April 6, 2024
Organization, Growth, HK, Gate, Financial services, Binance, OKX, GBS, Ecosystem, Convention center, Treasury

PANAMA CITY, April 6, 2024 /PRNewswire/ -- From April 6th to April 9th, Gate.io actively participated in the 2024 Hong Kong Web3 Festival held at Hall3FG of the Hong Kong Convention and Exhibition Centre.

Key Points: 
  • PANAMA CITY, April 6, 2024 /PRNewswire/ -- From April 6th to April 9th, Gate.io actively participated in the 2024 Hong Kong Web3 Festival held at Hall3FG of the Hong Kong Convention and Exhibition Centre.
  • The first day of the 2024 Hong Kong Web3 Festival welcomed thousands of Web3 enthusiasts and thought leaders from around the world.
  • Gate.io 's booth at the festival was a resounding success, showcasing its leading Web3 ecosystem and highlighting advancements in security and compliance.
  • Gate.io 's active involvement in the Hong Kong Web3 Festival underscores its commitment to engaging with industry leaders and nurturing the growth of Web3.

New York Life Group Benefit Solutions Launches New Tool to Tackle Parental Leave Uncertainty

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Consumer, Parenting, Insurance, Human Resources, Finance, Uncertainty, NYL, Confusion, Parent, Parental leave, Research, Child, Pregnancy, GBS

A recent survey by New York Life Group Benefit Solutions (NYL GBS) reveals a sense of uncertainty and financial unpreparedness surrounding pregnancy, childbirth, and parental leave among adults planning to have a child.

Key Points: 
  • A recent survey by New York Life Group Benefit Solutions (NYL GBS) reveals a sense of uncertainty and financial unpreparedness surrounding pregnancy, childbirth, and parental leave among adults planning to have a child.
  • In response, NYL GBS today announced the launch of myLeaveGuideSM, an online tool that simplifies parental leave planning.
  • "myLeaveGuideSM helps cut through the confusion of parental leave," said Meghan Shea, Vice President and Head of Strategy and Solutions at New York Life Group Benefit Solutions.
  • “Now, through our collaboration with New York Life Group Benefit Solutions, myLeaveGuideSM can help individuals more confidently navigate these often complex regulations."

SSON Research & Analytics Announces Winner and Runner-Up for World's Best GBS Award 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Award, Organization, IBM Consulting, GBS, Allianz, Shared services

NEW YORK, April 4, 2024 /PRNewswire-PRWeb/ -- SSON Research & Analytics, the global data analytics center of the Shared Services & Outsourcing Network (SSON), has released the winner and runner-up of the prestigious 2024 World's Best GBS Award. This recognition celebrates exceptional Global Business Services (GBS) that embody innovation and deliver significant value to the enterprise beyond traditional process efficiency.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire-PRWeb/ -- SSON Research & Analytics, the global data analytics center of the Shared Services & Outsourcing Network (SSON), has released the winner and runner-up of the prestigious 2024 World's Best GBS Award.
  • A meticulous selection process involving award judges and SSON Research & Analytics leadership determines the top five finalists, winner, and runner-up.
  • To share some of the insights underpinning the Award winner's achievements, SSON Research & Analytics will present two webinars:
    April 23rd: Introducing Allianz Services, winner of the 2024 World's Best GBS Award.
  • An in-depth analysis of GBS performance based on data from the 2024 World's Best GBS Award applications.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Emagia to Showcase Generative AI-Powered Autonomous Finance Innovations for Shared Services at SSOW 2024

Retrieved on: 
Wednesday, March 20, 2024
Synthetic media, Knowledge, Artificial intelligence, AI, IBM Consulting, GBS, Booth, Shared services, Expo Hall, Generative, Gia, Cryptocurrency

SANTA CLARA, Calif., March 20, 2024 /PRNewswire-PRWeb/ -- Shared Services and Outsourcing Week (SSOW) 2024, the premier conference for Global Business Services (GBS) and shared services executives, is set to take place from March 25-28, 2024, in Orlando, FL. This year's theme, "Transforming & Delivering Business Outcomes," promises to address the latest trends in autonomous finance operations, artificial intelligence (AI), and digitization.

Key Points: 
  • Emagia, the leading provider of Autonomous Finance Platforms for Order-to-Cash, announced its participation as a sponsor, exhibitor, and presenter at the Shared Services and Outsourcing Week (SSOW) 2024, March 25-28.
  • SANTA CLARA, Calif., March 20, 2024 /PRNewswire-PRWeb/ -- Shared Services and Outsourcing Week (SSOW) 2024, the premier conference for Global Business Services (GBS) and shared services executives, is set to take place from March 25-28, 2024, in Orlando, FL.
  • "Emagia is excited to share our knowledge and showcase our innovations focused on autonomous finance operations, AI copilots, and the changing nature of work for global shared services," said Founder & CEO Veena Gundavelli.
  • Emagia will showcase its latest Generative AI-powered Autonomous Finance Platform for Order-to-Cash at the Expo Hall, highlighting Gia, its flagship Generative AI co-pilot.

Cepheid Receives FDA Clearance for Xpert® Xpress GBS

Retrieved on: 
Monday, March 11, 2024
PCR, Obstetrics, Streptococcus, Rheumatic fever, EVP, INT, Risk, Cepheid variable, Antibiotic prophylaxis, Antimicrobial stewardship, Fungal infection, Genome, Woman, American College, GBS, Negative, ACOG, Infant, Food, Sintering

SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). This next-generation test incorporates new dual targets in highly-conserved regions of the GBS genome to improve sensitivity and bacterial strain coverage. The test is designed for use on Cepheid's GeneXpert® systems.

Key Points: 
  • SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).
  • Xpert Xpress GBS allows for the use of intrapartum direct PCR testing for women with unknown or unavailable antepartum GBS status.
  • With the capability of returning positive results as early as 30 minutes,2 Xpert Xpress GBS can provide real-time GBS status and inform decisions about empiric antibiotic prophylaxis if appropriate, to prevent GBS transmission during birth.
  • With Xpert Xpress GBS, Cepheid continues to provide fast, accurate, and reliable PCR solutions to facilitate evidence-based treatment and improved clinical care.

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

Retrieved on: 
Wednesday, February 21, 2024
Doctor of Philosophy, MD, Neurology, Complement component 1q, University, GBS, MBBS, Medicine, Sintering

BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET. To register, click here.

Key Points: 
  • Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, Professor Emeritus of Johns Hopkins University School of Medicine
    BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET.
  • To register, click here .
  • The event will feature GBS experts who will provide an overview of Guillain-Barré syndrome (GBS), the most common cause of acute neuromuscular paralysis:
    Presentations from GBS experts and Annexon management will highlight:
    Targeting C1q in GBS with ANX005, Annexon's investigational monoclonal antibody designed to inhibit C1q and stop classical complement pathway activation before it starts
    A live question and answer will follow formal presentations.